Results for "Entrada Therapeutics"

The venture capital firm reduced its holdings in the biotechnology company through recent market transactions, reflecting standard portfolio rebalancing activities.

Investment firm Mpm Bioventures has sold shares worth $461,545 in biotech company Entrada Therapeutics, according to recent filings.

Several publicly traded biotechnology and healthcare companies have disclosed new equity awards designed to attract and retain key personnel. These filings comply with Nasdaq Listing Rule 5635(c)(4), which permits such inducement grants outside standard executive compensation plans.

Entrada Therapeutics experienced a significant stock drop following the release of early-stage trial data for its Duchenne muscular dystrophy therapy.

Investment vehicles managed by MPM Bioventures have sold approximately $615,777 worth of shares in biotechnology firm Entrada Therapeutics. The transaction reflects routine portfolio adjustments by the venture capital group.

Entrada Therapeutics reported a GAAP EPS of -$0.94, beating estimates, but its revenue of $1.3M missed expectations.